CDK to Offer Dealers a More Open and Inclusive DMS Platform
11.7.2017 09:30:00 EEST | Business Wire | Press release
Today, CDK Global’s International business revealed plans for an evolution of its dealer management platform that will enable automotive retailers to manage the customer journey from online to offline more efficiently and profitably. Building on CDK’s market-leading position, a new programme of openness in platform development will allow selected third-party applications to integrate with CDK’s core dealer management platform and better enable end-to-end automotive commerce.
The new move coincides with the launch of a rapid product development programme, which will enable CDK to deliver new innovations to global markets. This approach will see CDK research and development teams work more closely with retailers, partners and consumers to identify issues, explore new efficiencies and develop new products and services. Examples of recent innovations include integration between CitNow, a video capture product to increase transparency and trust in the aftersales process and the DMS, but also new products such as SmartPay in Demark, a mobile payment solution for service departments.
Neil Packham, President of CDK International, said: “The world has moved on from all customer interaction being inside a dealership. Now the digital journey plays a major role, so customer interactions can occur anywhere, at any time – often in a virtual space. We already use vehicle manufacturer interfaces to provide a more joined-up customer experience and save many work hours for dealership staff. Now, we are developing new innovations and partnerships that will complement and evolve existing products, enabling retailers to be even more efficient, effective, and profitable.”
Through its existing partnership programmes with manufacturers, CDK has already developed and released a proven suite of interfaces that allow access to multiple-systems and network-wide information within its integrated Autoline Drive DMS software.
The two-way sharing of vehicle and other data between retailers and vehicle manufacturers is an industry-first that has the potential to free-up thousands of hours for dealership staff and improve the customer experience. For example, a short code can be generated from a selected manufacturer’s online car configurator, using factory build data for exact specifications, which can then be used in dealership processes and throughout the ownership cycle.
Now, as part of CDK’s product evolution programme, retailers will have the option of integrating partner applications with the core DMS platform. Whether it is a vehicle manufacturer-mandated showroom system, dedicated CRM software or a marketing tool, CDK’s new approach will enable selected systems to integrate with the DMS platform and communicate with each other.
CDK Global invests heavily in research and development, identifying the challenges faced by automotive retailers all over the world to help develop new technologies that keep dealerships up to date with changing consumer preferences. As a technology partner for vehicle manufacturers and dealer networks, CDK helps transform retailers by enabling total integration of DMS with dealership operations, delivering innovative management and analysis tools to allow easy adoption of emerging technologies in automotive retail.
Notes to editors
About CDK Global
With more than $2 billion in revenues, CDK Global (Nasdaq:CDK) is a leading global provider of integrated information technology and digital marketing solutions to the automotive retail and adjacent industries. Focused on evolving the automotive retail experience, CDK Global provides solutions to dealers in more than 100 countries around the world, serving approximately 28,000 retail locations and most automotive manufacturers. CDK's solutions automate and integrate all parts of the dealership and buying process from targeted digital advertising and marketing campaigns to the sale, financing, insuring, parts supply, repair and maintenance of vehicles.
For more information about CDK in the UK, visit www.cdkglobal.co.uk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170710006512/en/
Contact information
For further information, images or comment, please contact PFPR
Communications:
Laura Hatton
T: +44 (0)1622 766521
M
: +44 (0)7515 060527
E:
laura.hatton@pfpr.com
or
Matt
Moore
T: +44 (0)1622 776681
M: +44 (0)7715 075992
E:
matt.moore@pfpr.com
or
Jon
Visscher
T: +44 (0)1622 776680
M: +44 (0)7816
906794
E:
jon.visscher@pfpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
